Jacobio Pharma Reports Key Milestones and Annual Results for 2025 Jacobio Pharma shares its significant yearly achievements for 2025, highlighting breakthroughs in KRAS-targeted therapies and clinical advancements.

Jacobio Pharma Reports Key Milestones and Annual Results for 2025 #China #Beijing #Jacobio_Pharma #KRAS_therapies #ADC_programs

Jacobio Pharma Partners with AstraZeneca for KRAS Cancer Treatment Breakthrough Jacobio Pharma has signed a major deal with AstraZeneca for its Pan-KRAS inhibitor JAB-23E73, enhancing global cancer treatment efforts.

Jacobio Pharma Partners with AstraZeneca for KRAS Cancer Treatment Breakthrough #China #Beijing #AstraZeneca #Jacobio_Pharma #JAB-23E73

Jacobio Pharma Showcases Promising Pre-Clinical Findings of JAB-23E73 at International Conference Jacobio Pharma unveiled notable pre-clinical results of JAB-23E73, a pan-KRAS inhibitor, at the AACR-NCI-EORTC conference, highlighting its effectiveness.

Jacobio Pharma Showcases Promising Pre-Clinical Findings of JAB-23E73 at International Conference #China #Beijing #Jacobio_Pharma #JAB-23E73 #pan-KRAS_Inhibitor

Jacobio Pharma Partners with Oceanpine Capital for Oncology Pipeline Advancement Jacobio Pharma has joined forces with Oceanpine Capital to enhance its oncology pipeline, focusing on innovative cancer therapies and operational efficiency.

Jacobio Pharma Partners with Oceanpine Capital for Oncology Pipeline Advancement #China #Beijing #oncology #Jacobio_Pharma #Oceanpine_Capital

Jacobio Pharma Reports Strong Growth and Breakthroughs in Interim Results for 2025 Jacobio Pharma has announced robust interim results for 2025, highlighting significant revenue growth, reduced losses, and promising advancements in its pipeline of cancer therapies.

Jacobio Pharma Reports Strong Growth and Breakthroughs in Interim Results for 2025 #China #Beijing #cancer_therapy #Jacobio_Pharma #glecirasib

Jacobio Pharma's Clinical Trial Application for BET Inhibitor JAB-8263 Approved for Autoimmune Diseases Jacobio Pharma has received approval for their Phase I/II clinical trial application for the BET inhibitor JAB-8263 aimed at treating autoimmune diseases.

Jacobio Pharma's Clinical Trial Application for BET Inhibitor JAB-8263 Approved for Autoimmune Diseases #China #Beijing #Jacobio_Pharma #BET_Inhibitor #JAB-8263

Jacobio Pharma Reports Impressive Annual Revenue Growth For 2024 Jacobio Pharma has announced its annual results for 2024, showcasing strong revenue growth and significant advancements in cancer treatment developments.

Jacobio Pharma Reports Impressive Annual Revenue Growth For 2024 #China #Beijing #Jacobio_Pharma #R&D #glecirasib

Jacobio Pharma Unveils Promising BET Inhibitor Data for Treating Myelofibrosis at 2024 ASH Annual Meeting Jacobio Pharma has presented promising preliminary data on its BET inhibitor, JAB-8263, for myelofibrosis treatment at the 2024 ASH Annual Meeting.

Jacobio Pharma Unveils Promising BET Inhibitor Data for Treating Myelofibrosis at 2024 ASH Annual Meeting #China #Beijing #Myelofibrosis #Jacobio_Pharma #BET_Inhibitor